A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Best Overall Response Rate (bORR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma

Time frame: Baseline up to EOT (approximately 9 months)

Duration of Response (DoR)

Time frame: From the date of the first occurrence of a documented CR or partial response (PR) to the date of progression, relapse, or death from any cause, whichever occurs first (up to approximately 24 months)

Duration of Complete Response (DoCR)

Time frame: From the date of the first occurrence of a documented CR to the date of progression, relapse, or death from any cause, whichever occurs first (up to approximately 24 months)

PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma

Time frame: Baseline up to end of study (approximately 24 months)

Event Free Survival (EFS) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma

Time frame: From the start of glofitamab treatment to any treatment failure including disease progression, relapse, initiation of new antilymphoma therapy (NALT), or death from any cause, which occurs first (up to approximately 24 months)

Overall Survival (OS)

Time frame: From the start of glofitamab treatment until the date of death from any cause (up to approximately 24 months)

Time to Next Treatment (TTNT)

Time frame: From the start of glofitamab treatment to the initiation of next-line treatment (up to approximately 24 months)